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Introduction
Clostridium perfringens, a Gram-positive, anaerobic 
bacillus, is a bacterium commonly found in nature. Its 
presence can be confirmed in both the external envi-
ronment (water, soil, and sewage) as well as in the diges-
tive tract of humans and animals, where it is part of the 
microbiome. The important carriers of this microbe are 
the elderly and people engaged in the processing and 
distribution of food. Nonetheless, its ability to produce 
numerous toxins and enzymes as well as to form spores 
makes this bacterium a dangerous pathogen of humans 
and animals (Kędzielska et al. 2012).
The scientific literature indicates several toxins pro-
duced by C. perfringens that play a vital role in the path-
ogenicity of this bacterium, they are: alpha (α, C. per-
fringens alpha toxin – CPA) and a synergistic theta, i.e. 
perfringolysin (θ, perfingolysin O – PFO), as well as beta 
(β, C. perfringens beta toxin – CPB), epsilon (ε, epsi-
lon toxin – ETX), iota (ι, iota toxin – ITX), enterotoxin 
(C. perfringens enterotoxin – CPE), necrotic enteritis 
B-like toxin (NetB), and β2 toxin, discovered in 1997, 
the role of which is not fully explained and still requires 
further research (van Asten et al. 2010; Brzychczy-
Włoch and Bulanda 2014; Navarro et al. 2018). It is 
known that β2-toxin is produced by animal strains of 
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A b s t r a c t
This study conducts a comparative phenotypic and genetic analysis of C. perfringens strains isolated from two patients hospitalized at the 
same time in 2017 in the surgical ward of the Provincial Specialist Hospital in Włocławek (Kujawsko-Pomorskie Province) who devel-
oped necrotizing soft tissue infections (NSTI). To explain the recurring cases of this infection, a comparative analysis was performed for 
these strains and the ones originating from infections recorded at the same hospital in three patients with gas gangrene in 2015. The two 
C. perfringens isolates studied in 2017 (8554/M/17 from patient No. 1 and 8567/M/17 from patient No. 2) had identical biochemical profiles. 
A comparison of research results using multiplex PCR from 2017 with a genetic analysis of strains from 2015 enabled us to demonstrate 
that the strains currently studied have the genes encoding the same toxins (α and β2) as the two strains analyzed in 2015: no. 7143 (patient 
No. 3) and no. 7149 (patient No. 2). A comparative analysis of the strain profiles obtained with pulsed-field gel electrophoresis (PFGE) 
in 2017 with the results from 2015 has found one identical and genetically unique restriction profile, corresponding to one clone of 
C. perfringens comprising of two strains: no. 8567/M/17 (patient No. 2 in 2017) and no. 7143 (patient No. 3 in 2015). The epidemiological 
data and detailed analysis of the course of both events suggest that this clone of C. perfringens possibly survived in adverse conditions of 
the external environment in the operating block of this hospital for many months.
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C. perfringens, especially in the course of necrotic enteri-
tis in pigs. Studies on human strains of this bacterial 
species, isolated from patients with food poisoning, an 
antibiotic-associated diarrhea and sporadic diarrhea, but 
also from healthy carriers, have shown that, in some 
cases, they can have cpb2 gene for β2-toxin (Johansson 
et al. 2006, van Asten et al. 2010; Allaart et al. 2014).
Owing to their ability to produce various toxins, 
strains belonging to the species C. perfringens were 
divided into 6 toxinotypes, A – G, which are respon-
sible for gastrointestinal tract infections in humans 
(types A, C, F) and animals (types B, C, D, E, G) as 
well as severe soft tissue infections in humans and ani-
mals (type A) (Stevens et al. 2012; Navarro et al. 2018; 
Rood et al. 2018).
The term necrotizing soft tissue infections (NSTI) 
com pri ses a group of diseases (especially necrotizing 
fasciitis – NF) causing rapid and extensive soft tissue 
necrosis, which often leads to systemic infection, shock, 
and multiple organ failure, and ultimately, death (Ste-
vens et al. 2017). These infections have different causes, 
risk factors, location, and pathomechanisms. NSTIs are 
often divided into two types. Type 1 is a multi-bacterial 
infection, the significant parts of which are anaerobic 
bacteria (among others, from the genus Bacteroides or 
Clostridium) and facultative anaerobes (among others 
of the family Enterobacteriaceae). It is often diagnosed 
in the elderly and the risk factors are diabetes, bedsores, 
hemorrhoids or anal surgery, and urological surgery or 
gynecological procedures. A peculiar infection of this 
type is a Fournier gangrene, which may develop as sec-
ondary to damaged mucous membranes of the gastro-
intestinal tract or urinary tract (Żaba et al. 2009; Stevens 
et al. 2017; Kuzaka et al. 2018). C. perfringens is listed as 
one of the numerous bacteria identified in the course 
of this infection. Although in recent years, its share in 
the infection seems to be getting smaller (Kuzaka et al. 
2018), the literature still describes cases of Fournier gan-
grene in which C. perfringens was cultured among the 
other infectious agents (Wróblewska et al. 2014; Stevens 
et al. 2017). Type 2 of NSTI is usually associated with 
infection with a single bacterial species (e.g. MRSA) 
and often affects limbs. Some people distinguish Type 3, 
i.e. infection caused by a particular bacterial species: 
Aeromonas hydrophila, Vibrio vulnificus or a  species 
from the genus Clostridium, which is most often isolated 
from gas gangrene cases (Stevens et al. 2017).
From the point of view of epidemiology and future 
management in cases of recurring NSTI in the same 
hospital, it is important to identify the differences and 
similarities among bacterial strains from every patient. 
The use of molecular methods allows for fast and pre-
cise identification of the bacteria isolated. The objective 
of this study is a comparative phenotypic and genetic 
analysis of C. perfringens strains isolated from two 
patients hospitalized at the same time in 2017 in the 
Provincial Specialist Hospital in Włocławek (Kujawsko-
Pomorskie Province) who developed soft tissue infec-
tions. Trying to explain recurring cases of this infection, 
we also carried out an additional comparative analysis 
of C. perfringens strains isolated in 2017 with the strains 
isolated in 2015 from three patients with gas gangrene 
in the same hospital that have been already described 
by our team (Brzychczy-Włoch et al. 2016).
Experimental
Materials and Methods
The study involved the microbiological analysis of 
C. perfringens strains isolated from biological speci-
mens originating from two patients with NSTI who 
were hospitalized between 17th May 2017 and 4th July 
2017 in a particular Department of General Surgery 
in the hospital in Włocławek. The analysis of micro-
biological and epidemiological data concerning three 
patients hospitalized in the same hospital between 
15th April 2015 and 20th April 2015 (Brzychczy-Włoch 
et al. 2016) was also performed.
Source of the isolates and epidemiological data 
from 2017. Patient 1. A man, aged 60, admitted on 
17.05.2017 to the General Surgery Department due to 
critical vascular insufficiency of the lower limbs. Due 
to the ischemia of the lower skin flap covering the 
stump and inflammatory infiltration in the postop-
erative wound on 31.05.2017, the stump wound was 
swabbed. The growth of C. perfringens on microbiologi-
cal media under anaerobic conditions and of coagulase-
negative staphylococci (CNS) under aerobic conditions 
was demonstrated. Control swabs from the healing 
wound were microbiologically negative. The microbio-
logical examination of the blood taken from the patient 
did not show bacterial growth.
Patient 2. A man, aged 60, admitted urgently on 
31.05.2017 to the General Surgery Department due to 
anorectal abscess. In the course of the diagnostics under-
taken, disseminated sigmoid colon cancer was eventu-
ally diagnosed. Past medical history revealed a stay in 
the same unit in May 2014, when the patient underwent 
surgery due to right-sided incarcerated inguinal hernia.
During the relevant hospitalization, on 31.05.2017, 
abscess contents were collected from the patient for 
microbiological diagnostics. Microbiological testing 
of the purulent content detected the growth of Bac-
teroides fragilis and C. perfringens on microbiological 
media under anaerobic conditions, and Escherichia coli 
and Pseudomonas aeruginosa under aerobic conditions. 
Microbiological testing of the patient’s blood did not 
show bacterial growth. During the microbiological 
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examination of a rectal swab carried out on 6.06.2017, 
growth of C. perfringens was detected.
The prevention of epidemic outbreak and epidemio-
logical investigations were initiated. Contact isolation 
was employed with both patients. Lavasepsis was used 
for wound dressing with 0.9% NaCl solution and super-
oxidized solution in the form of Microdacyn (Oculus). 
A sporicidal agent, Incidin Active (Ecolab), was applied 
for surface disinfection in the ward. When microbio-
logical results were obtained, the entire General Surgery 
Department and the Main Operating Block were cov-
ered by the control. Growth of C. perfringens was not 
demonstrated in cultures collected from the wounds of 
other patients, the skin of the staff ’s hands, or on the 
surfaces in all rooms and on the tools.
Microbiological diagnostics of C. perfringens stra-
ins. Samples of two patients were collected during a rou-
tine check-up by medical staffs and were diagnosed in 
the Department of Microbiological Diagnostics of the 
Provincial Specialist Hospital in Włocławek. Specimens 
from the patients (wound swab containing activated car-
bon (COPAN) from patient No. 1 and abscess contents 
from patient No. 2) were put into sterile test tubes with 
a transport medium. The culture was carried out on 
Columbia Agar (BioMerieux) as well as in the fluid thio-
glycollate medium with resazurin (BioMaxima). Solid 
media with the inoculated materials were incubated 
under aerobic conditions at 37°C for 48 h and under 
anaerobic conditions at 37°C for 24 h, and the liquid 
medium under aerobic conditions (with a closed cap) 
at 37°C for 48 h. Identification of the cultured bacte-
ria was carried out using the Vitek 2 compact system 
(BioMérieux). The biochemical patterns for two bacte-
rial isolates were received with the use of the ANC ID 
card of the Vitek 2 compact system (BioMérieux).
In view of the fact that the same bacterial species, 
C. perfringens, was isolated from both patients and 
because of its pathogenic potential and epidemiologi-
cal consequences, the following strains of C. perfrin-
gens: from patient No. 1 – isolate no. 8554/M/17; from 
patient No. 2 – isolate no. 8567/M/17, were preserved 
and transferred to the Chair of Microbiology, Jagiel-
lonian University Medical College, Krakow, Poland for 
further studies. The C. perfringens strain cultured from 
the specimen obtained from a rectal swab from patient 
No. 2 was not preserved, which made it impossible to 
conduct further analyses for this strain.
The strains 8554/M/17 and 8567/M/17 were stored 
with the use of Cryobank (BioMaxima) at –70°C. 
C. perfringens 3624 ATCC (The American Type Cul-
ture Collection) standard was used as a reference strain.
Antibiotic susceptibility testing. To determine the 
drug-resistance profiles, the E-test method was used, 
enabling determi nation of MIC (Minimal Inhibitory 
Concentration) for: amoxicillin – AML, penicillin – P, 8
55
4/
M
/1
7 
M
IC
(P
at
ie
nt
 1
) 
m
g/
l 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
1.
5 
0.
04
7 
0.
50
 
0.
50
 
0.
50
 
4 
0.
19
 
0.
01
6 
0.
03
2
 
S/
R 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
R 
S 
S 
R 
S 
R 
S 
S 
S
85
67
/M
/1
7 
M
IC
(P
at
ie
nt
 2
) 
m
g/
l 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
0.
01
6 
2 
0.
04
7 
0.
50
 
0.
50
 
0.
50
 
4 
0.
12
5 
0.
01
6 
0.
03
2
 
S/
R 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
R 
S 
S 
R 
S 
R 
S 
S 
S
Ta
bl
e I
A
nt
ib
io
tic
 su
sc
ep
tib
ili
ty
 fo
r C
. p
er
fri
ng
en
s i
so
la
te
s (
Th
e E
-te
st 
m
et
ho
d,
 ac
co
rd
in
g 
to
 E
U
CA
ST
 2
01
7)
.
A
M
L 
– 
am
ox
ic
ill
in
, P
 –
 p
en
ic
ill
in
, P
RL
 –
 p
ip
er
ac
ill
in
, X
L 
– 
am
ox
ic
ill
in
/c
la
vu
la
ni
c a
ci
d,
 C
RO
 –
 ce
ftr
ia
xo
ne
, C
TX
 –
 ce
fo
ta
xi
m
e, 
D
O
R 
– 
do
rip
en
em
, E
TP
 –
 er
ta
pe
ne
m
, I
M
P 
– 
im
ip
en
em
,
M
EM
 –
 m
er
op
en
em
, M
XF
 –
 m
ox
ifl
ox
ac
in
, T
EC
 –
 te
ic
op
la
ni
n,
 V
A
 –
 v
an
co
m
yc
in
, E
 –
 er
yt
hr
om
yc
in
, D
A
 –
 cl
in
da
m
yc
in
, T
E 
– 
te
tr
ac
yc
lin
e, 
C 
– 
ch
lo
ra
m
ph
en
ic
ol
, M
 –
 m
et
ro
ni
da
zo
le,
RD
 –
 ri
fa
m
pi
ci
n,
 M
IC
 –
 M
in
im
al
 In
hi
bi
to
ry
 C
on
ce
nt
ra
tio
n,
 S
/R
 –
 su
sc
ep
tib
ili
ty
, R
 –
 re
sis
ta
nt
, S
 –
 su
sc
ep
tib
le
Is
ol
at
e
no
.
Pe
ni
ci
lli
ns
C
ep
ha
lo
sp
or
in
s
Ca
rb
ap
en
em
s
Fl
uo
ro
-
qu
in
o-
lo
ne
s
G
ly
co
pe
pt
id
e
an
d 
lip
o-
 
gl
yc
op
ep
tid
es
M
ac
ro
lid
es
,
in
co
sa
m
id
es
Te
tr
a-
cy
cli
-
ne
s
M
isc
el
la
ne
ou
s a
ge
nt
s
RD
M
C
TE
D
A
E
VA
TE
C
M
XF
M
EM
IM
P
ET
P
D
O
R
CT
X
CR
O
XL
PR
L
P
A
M
L
Salamon D. et al. 3326
piperacillin – PRL, amoxicillin/clavulanic acid –  XL, 
ceftriaxone – CRO, cefotaxime – CTX, doripenem 
–  DOR, ertapenem – ETP, imipenem – IMP, mero-
penem –  MEM, moxifloxacin – MXF, erythromy-
cin – E, clindamycin – DA, tetracycline – TE, chlor+ 
amphenicol – C, metronidazole – M, rifampicin – RD 
and with Glycopeptide Resistance Detection (GRD) 
for: teicoplanin –  TEC and vancomycin –  VA. The 
results were interpreted according to The European 
Committee on Antimicrobial Susceptibility Testing 
(EUCAST 2017) – Table I.
PCR multiplex. To isolate DNA, the Genomic Mini 
Set (A&A Biotechnology) was used according to the 
manufacturer’s protocol. The presence of the genes 
encoding toxins of C. perfringens was confirmed using 
multiplex PCR amplification according to van Asten 
et al. (2009) with specific primers (Genomed). The 
following fragments of the genes were detected (the 
gene product, length of the fragment): cpa (α-toxin, 
324 bp); cpb (β-toxin, 195 bp); cpb2 (β2-toxin, 548 bp); 
etx (ε-toxin, 376 bp); iap (ζ-toxin, 272 bp); cpe (entero-
toxin, 485 bp). The final images from elec trophoresis 
were processed using QuantityOne soft ware, as well as 
GelDoc2000 device (Bio-Rad, USA).
Molecular typing with PFGE. The chosen C. per-
fringens isolates underwent molecular typing using the 
PFGE method according to the methodology described 
by Maslanka et al. (1999). Chromosomal DNA of the 
bacterial strains was isolated in agarose blocks and 
then digested with the use of restriction enzyme SmaI 
(MBI Fermentas). Electrophoretic separation was per-
formed with the CHEF-DR II (Bio-Rad) instrument 
and restriction analysis was carried out using the Gel-
Compar II (Applied Maths) software with the applica-
tion of UPGMA clustering method and Jaccard index. 
The obtained genetic profiles were interpreted accord-
ing to the guidelines given by van Belkum et al. (2007).
The profiles of the strains under investigation that 
were obtained using PCR multiplex and PFGE were 
compared with restriction patterns of the strains 
that came from the event in 2015, when in the Ortho-
pedics and Traumatology Department of the same hos-
pital, three cases of gas gangrene caused by C. perfrin-
gens were detected simultaneously (Brzychczy-Włoch 
et al. 2016).
Results
The two C. perfringens isolates studied (8554/M/17 
from patient No. 1 and 8567/M/17 from patient No. 2) 
had identical biochemical profiles. Based on the results 
obtained using E-test, the same pattern of antibiotic 
susceptibility of the strains from the two examined 
patients was demonstrated (Table I).
Multiplex PCR confirmed the presence of the cpa 
gene encoding α-toxin for both C. perfringens isolates 
studied. Moreover, both strains demonstrated the pres-
ence of the cpb2 gene encoding β2-toxin (Fig. 1). A com-
parison of the results from 2017 and the genetic analysis 
of the strains from the event in 2015 enabled us to dem-
onstrate that the currently examined strains have the 
genes encoding the same toxins (α and β2) as the two 
strains analyzed in 2015: no. 7143 (patient No. 3) and 
no. 7149 (patient No. 2) (Brzychczy-Włoch et al. 2016).
As a result of the molecular analysis conducted 
using PFGE, two genetically different, unique restric-
tion profiles were found corresponding to two differ-
ent clones of the C. perfringens isolates studied in 2017: 
isolate no. 8554/M/17 – clone A; isolate no. 8567/M/17 
– clone B (Fig. 2A).
Profiles of the strains under investigation that 
were obtained using PFGE were then compared with 
restriction patterns of the strains from the event in 2015 
(Brzychczy-Włoch et al. 2016). A comparative analy-
sis of PFGE profiles from 2017 and the results from 
the event from 2015 found one identical and geneti-
cally unique restriction profile, corresponding to one 
clone of C. perfringens for two strains: no. 8567/M/17 
(patient No. 2 in 2017) and no. 7143 (patient No. 3 in 
2015) (Fig. 2B).
Fig. 1. Detection of genes encoding virulence factors of C. per- 
frin gens isolates in 2017 tested by multiplex PCR.
Legend: M – size marker,
 1 – C. perfringens isolate no. 8567/M/17 from patient no. 2
 2 – C. perfringens isolate no. 8554/M/17 from patient no. 1
 3 – reference strain of C. perfringens ATCC 3624
 cpb2 – gene of β2-toxin; cpa – gene of α-toxin
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Due to this fact, an attempt was undertaken to find 
a  connection between patient No. 2 from 2017 and 
patient No. 3 from 2015. In the course of an epidemio-
logical investigation, it was only found that both patients 
were hospitalized in the same hospital, but they were 
in different wards at different times. The patient from 
whom the strain no. 7143 was isolated (patient No. 3) 
was hospitalized in April 2015 at the Department of 
Orthopedics and Traumatology. The currently described 
patient No. 2 from whom strain no. 8567/M/17 was iso-
lated in 2017 was in the General Surgery Department in 
May 2014. Both patients underwent surgery in the main 
operating block of the hospital. Kinship, close contact, 
possession of the same animals and residence in each 
other’s neighborhood were excluded.
Discussion
The cases presented above illustrate the clinical 
picture of necrotizing soft tissue infection, caused by 
C. perfringens toxinotype A. The infection leading to 
amputation of the left lower limb in the patient No. 1 
makes us to assume that he developed type  3 NSTI. 
Atherosclerosis of the lower extremities, alcoholism, 
and neuropathy with subsequent vascular insufficiency 
contributed to the rapid progression of the disease. The 
course of the infection in patient No. 2, which was clas-
sified as Fournier gangrene and isolation of the etio-
logic agent from the wound, i.e. C. perfringens, as well 
as medical history pointing to decreased immunity 
and advanced neoplastic disease of the large intestine, 
allowed to confirm this infection as type 1 NSTI.
The results of microbiological testing with pheno-
typic methods (biochemical patterns and antibiotic 
susceptibility testing) did not demonstrate differences 
between the strains isolated from biological specimens 
from the patients. On the other hand, the application 
of molecular methods allowed to characterize each of 
them accurately and compare them with strains iso-
lated during the epidemiological investigation, which 
took place in the same hospital during the event in 2015 
(Brzychczy-Włoch et al. 2016).
Determination of the toxinotype of C. perfringens 
isolates was possible owing to the use of multiplex 
PCR. The strains identified for both patients described 
Fig. 2. Genetic profiles of C. perfringens isolates, subjected to DNA digestion by restriction enzyme SmaI
with the use of pulsed-field gel electrophoresis (PFGE) and GelCompar II software.
Legend: A – Comparison of two isolates from 2017; B – comparison of five isolates: three from 2015 and two from 2017
 8554/M/17 – C. perfringens isolate isolated from patient no. 1 in 2017;  ATCC 3624 – reference strain of C. perfringens
 8567/M/17 – C. perfringens isolate isolated from patient no. 2 in 2017
 7143 – C. perfringens isolate isolated from patient no. 3 in 2015; 7149 – C. perfringens isolate isolated from patient no. 2 in 2015
 7013 – C. perfringens isolate isolated from patient no. 1 in 2015
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in this study were type A and had the genes encoding 
α-toxin (cpa gene) and β2-toxin (cpb2 gene). The role of 
α-toxin, which is the main virulence factor in of C. per-
fringens in gas gangrene, seems to be well known and 
is chiefly associated with hemolysis and dermonecro-
sis. To the best of our knowledge, there is no evidence 
pointing to β2-toxin’s contribution to necrotizing soft 
tissue infections in humans. Despite this, in the work 
reporting three simultaneous cases of gas gangrene 
associated with C. perfringens type A strains in 2015, 
two patients carried the strains that had the cpb2 gene, 
indicated an extremely severe course of these infections 
(Brzychczy-Włoch et al. 2016). The presence of the 
gene for β2-toxin in C. perfringens strains causing soft 
tissue infections in humans requires further obser-
vation, which could be assisted by the application of 
genetic analysis of this pathogen in every clinical case 
involving C. perfringens.
Molecular diagnostics of the strains isolated also 
allowed their final differentiation and an attempt to 
determine their origin. Owing to macrorestriction 
analysis of chromosomal DNA combined with PFGE, 
it was possible to determine that the strain of the 
described patient No. 1 turned out to be different from 
the strains isolated from the patient No. 2. However, the 
identification of an identical restriction profile for the 
C. perfringens isolate from patient No. 2 and the profile 
of the strain isolated from one of the patients during 
the event in 2015 in the same hospital (isolate no. 7143 
from patient No. 3) deserves more attention. According 
to the literature, the species C. perfringens is character-
ized by remarkable diversity and numerous mutations 
due to the presence of genes encoding toxins not only 
in the chromosome but also in plasmids (Myers et al. 
2006; Park et al. 2016; Kiu et al. 2017). Hence, a ran-
dom detection of the presence of an identical strain 
in two distant, independent events is unlikely. How-
ever, a high genetic similarity between C. perfringens 
strains can be demonstrated when they cause epide-
miologically related infections (Johansson et al. 2006; 
Xiao et al. 2012). Our epidemiological analysis points to 
the fact that patient No. 2 (from the event in 2017) had 
already been subjected to a surgical procedure within 
the abdominal cavity in this hospital in 2014. There 
is a  possibility that he had already been a carrier of 
C. perfringens in the gastrointestinal tract at that time 
and that he became the source of the infection and as 
result of the surgical procedure the bacterium appeared 
in the operating block of the hospital. It is known that 
C. perfringens may be present everywhere, even in dust, 
and is capable of producing spores, which can survive 
in unfavorable conditions for many months (van Asten 
et al. 2010; Kędzielska et al. 2012; Brzychczy-Włoch and 
Bulanda 2014). In 2014, there was no reason for routine 
use of sporicidal substances in the operating block (no 
symptomatic cases of infection with the bacillus C. per-
fringens at the hospital). One should, then, take into 
consideration the possibility of survival of C. perfrin-
gens spores in the hospital after the hospitalization of 
patient No. 2 in 2014 and the possible infection of one 
of the three patients undergoing surgery in the same 
operating block in 2015. Even more, other connections 
between both patients were excluded (kinship or being 
neighbors). During the event in 2015, the appropriate 
epidemiological and protective procedures against an 
outbreak were implemented (including the application 
of sporicidal agents). Therefore, it is unlikely that the 
C. perfringens strain survived two more years in the 
operating block (Brzychczy-Włoch et al. 2016). Addi-
tionally, the result of rectal swab testing in patient No. 2 
in 2017 indicated that the isolate from that sample is an 
endogenous (own) strain of the patient. It was patient 
No. 2 who probably had been a carrier of the described 
C. perfringens strain in the gastrointestinal tract for 
years and his decreased immunity together with cancer 
created the favorable conditions for the growth of bac-
teria and development of infection in 2017 (Brzychczy-
Włoch and Bulanda 2014; Kuzaka et al. 2018).
Our research has some limitation as there are no 
environmental or hospital staff studies that could have 
precisely demonstrated the source where C. perfringens 
clone that was able to survive. However, owing to the 
application of molecular methods, it was possible to 
determine that the patients simultaneously hospital-
ized in 2017, in a single Department of General Surgery 
developed two different types of NSTI caused by two 
different C. perfringens clones. Archival data from 2015 
allowed the identification of an identical clone from 
the same hospital. The employment of genetic analy-
ses also enabled us to document, in the strains stud-
ied in 2015 and in 2017, the presence of the cpb2 gene 
encoding β2-toxin. Moreover, the epidemiological data 
and detailed analysis of the course of both events in 
the hospital made it possible to attempt to understand 
the reasons of the survival of the C. perfringens clone 
in the operating block and suggest that this bacterium 
may have survived in adverse conditions of the exter-
nal environment for many months, posing a potential 
threat to patients. Hence, compliance with the proce-
dures concerning the operating block hygiene must 
always be strictly observed. Maybe it is also worthwhile 
to consider modifying them and to introduce periodic 
(e.g. every three months) mandatory application of 
sporicidal agents regardless of whether there were clini-
cal cases of C. perfringens infection or not.
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